(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Jazz Pharmaceuticals's revenue in 2025 is $4,157,833,000.On average, 20 Wall Street analysts forecast JAZZ's revenue for 2025 to be $262,079,945,308, with the lowest JAZZ revenue forecast at $249,197,740,716, and the highest JAZZ revenue forecast at $272,774,605,724. On average, 20 Wall Street analysts forecast JAZZ's revenue for 2026 to be $279,033,412,672, with the lowest JAZZ revenue forecast at $245,248,008,176, and the highest JAZZ revenue forecast at $301,759,566,056.
In 2027, JAZZ is forecast to generate $300,240,438,156 in revenue, with the lowest revenue forecast at $263,659,838,324 and the highest revenue forecast at $338,097,105,424.